pharmaphorum

DECEMBER 23, 2022

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S. CellCentric, a U.K-based

Side effects 52

Side effects Patients Medical Medicine 52

Evolve Your Success

JUNE 13, 2023

Kelly currently thrives in diagnostic testing sales, specifically in a department that deals with skin cancer prognosis. — Watch the episode here Listen to the podcast here How To Sell Effectively In Diagnostic Testing Sales With Kelly Buber We have with us another special guest and he goes by the name of Kelly Buber.

Sales 52

Sales Medical sales Medical Doctors 52

European Pharmaceutical Review

MAY 11, 2023

Transformative treatments have exposed and tested the limitations of our value assessment and reimbursement systems. Rare, genetic diseases like SMA are prime targets for gene therapy, but by their very nature, early signs can be difficult to recognise, delaying diagnosis and treatment. percent of Europe’s annual healthcare spend.

Food and Drug Administration 69

Food and Drug Administration Government Healthcare Healthcare 69